Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Alto Neuroscience, Inc. ( (ANRO) ) is now available.
On May 31, 2025, Alto Neuroscience, Inc. entered into an Asset Purchase Agreement with Chase Therapeutics Corporation to acquire assets related to two novel drug combinations, CTC-501 and CTC-413, for $1.75 million upfront and potential milestone payments up to $71.5 million. The acquisition includes intellectual property rights and is expected to enhance Alto’s pipeline with ALTO-207, a promising treatment for treatment-resistant depression, and ALTO-208 for Parkinson’s disease. The transaction supports Alto’s strategy to expand its precision psychiatry platform and maintain its financial guidance, with cash expected to fund operations through 2028.
The most recent analyst rating on (ANRO) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Alto Neuroscience, Inc. stock, see the ANRO Stock Forecast page.
Spark’s Take on ANRO Stock
According to Spark, TipRanks’ AI Analyst, ANRO is a Neutral.
Alto Neuroscience, Inc. faces significant financial challenges with zero revenue, increasing losses, and negative cash flows, reflecting in a low financial performance score. Despite some technical indicators suggesting short-term upward momentum, the stock’s valuation remains risky due to a negative P/E ratio and lack of dividends, resulting in an overall low stock score.
To see Spark’s full report on ANRO stock, click here.
More about Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision medicines for neuropsychiatric disorders. The company leverages its Precision Psychiatry Platform™ to measure brain biomarkers and aims to redefine psychiatry by creating personalized and effective treatment options.
Average Trading Volume: 265,946
Technical Sentiment Signal: Sell
Current Market Cap: $70.39M
For a thorough assessment of ANRO stock, go to TipRanks’ Stock Analysis page.